Humanigen Inc

Humanigen — Investor Presentation (January 2018)

26 slides from Humanigen's investor presentation, Jan 29, 2018

  1. Slide 1: Corporate Overview - January 29, 2018

    Developing Leading-Edge Immunotherapy, Oncology Treatments OTCQB: HGENwww.humanigen.com 1 With Goal of Potential Significant Near-Term Value Inflection | Corporate Overview - January 29, 2018

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements 2 This presentation contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management’s current knowledge, assumptions, judgment and expectations regarding

  3. Slide 3: Investor Overview

    Investor Overview Cutting-edge science monoclonal antibody biotechnology company – with improving financial profileDeveloping key asset (lenzilumab) for prevention of side effects associated with CAR-T – one of the hottest areas in biotechWorking with leading KOLs to start phase 1/2 trials Lenziluma

  4. Slide 4: CAR-T's 'Achilles Heel': Neurotoxicity and Cytokine Release Syndrome

    CAR-T’s ‘Achilles Heel’: Neurotoxicity (NT) and Cytokine Release Syndrome (CRS) – Key Impediments to Safe Use 4 64% had NT and 93% had CRS*~1/3 of patients had grade ≥3 NT, leading to ICU admissionMedian time to resolution of NT – 17 daysSeveral deaths Management of NT, CRS Is Limited Tocilizumab (I

  5. Slide 5: Time Course of NT and CRS Following CAR-T Infusion

    Time Course of NT and CRS Following CAR-T Infusion Lee, et al. Blood. 2014 July 10;124(2)188-195 5

  6. Slide 6: Recent Leading Research Shows GM-CSF Correlation to NT, CRS

    Z.J Roberts, et al. Leukemia & Lymphoma 2017. https://doi.org/10.1080/10428194.2017.1387905 Recent Leading Research Shows GM-CSF Correlation to NT, CRS 6 GM-CSF levels precede and modulate other cytokinesCorrelate with NT, CRS GM-CSF is a key biomarker associated with > grade 3 NT Locke, Neelapu et

  7. Slide 7: Scientific Basis for GM-CSF as Initiator in CAR-T Toxicity

    Scientific Basis for GM-CSF as Initiator in CAR-T Toxicity 7 GM-CSF may be a trigger – potentially switching CAR-T from cancer killing to off-target inflammation Inflammatory cascade potentially initiated by GM-CSFTrafficking and recruitment of myeloid cells to the tumor site through key chemokines

  8. Slide 8: CAR-T-related Neurotoxicity: Very high unmet medical need

    Very high unmet medical need No effective treatment; high-dose steroids may impact efficacy; not FDA approved or useful in preventionNo effective prophylaxis – which could minimize need for and time in ICU Fatal in ~5% patients; cytokine storm in cerebral spinal fluid CAR-T-related Neurotoxicity (NT

  9. Slide 9: Cytokine Release Syndrome

    GM-CSF implicated as upstream of other cytokinesExpect more CAR-T use (earlier lines of therapy, solid tumors, out-patient administration) and investment by big pharmaProphylaxis may allow for higher doses of CAR-T with greater efficacy In-patient readmission/ICU impacts payers CRS 9 CAR-T label req

  10. Slide 10: Kymriah and Yescarta Have Black-Box Warnings for NT, CRS

    Kymriah® and Yescarta® Have Black-Box Warnings for NT, CRS 10 Kymriah® label Yescarta® label

  11. Slide 11: Lenzilumab: Novel, First-in-Class Monoclonal Antibody

    Lenzilumab: Novel, First-in-Class Monoclonal Antibody 11 Lenzilumab First-in-class; binds to and neutralizes circulating GM-CSF Potent inhibitor of GM-CSF Safety, tolerability shown in multiple Phase 2 trialsEfficacy signals in eosinophilic asthma and RA Phase 2 trialsKey patent through 2029, extens

  12. Slide 12: GM-CSF May Be the Essential Bad Actor Driving CAR-T Toxicity

    Sentman, et al. www.jimmunol.org/content/197/12/4674.long; Coxford, et al. Immunity 2015 (43)510-514; Ishii, et al. Blood 2016 128:3358 Teachey, et al. Cancer Discov. 2016 June ; 6(6): 664–679. doi:10.1158/2159-8290.CD-16-0040; Lee, et al. Blood 2016 124:2:188; David M. Barrett et al. Blood 2016;128

  13. Slide 13: Prophylactic Use of Lenzilumab May Prevent CAR-T-related NT, CRS

    Prophylactic Use of Lenzilumab May Prevent CAR-T-related NT, CRS 13 1Grupp, et al. Blood 2012; 120:2604. 2Analysis of ZUMA-1, 30pt safety cohort, ASH 2017. 3Brudno, et al. Blood 2016; 127:26 Without concomitant IL-6 rise, may not respond to tocilizumab; early intervention with lenzilumab may be bene

  14. Slide 14: Lenzilumab Has an Established Safety Profile in >94 Patients

    Lenzilumab Has an Established Safety Profile in >94 Patients* 14 Study♦ Population Objectives Enrollment/Dose Safety Results Phase 1 Single-dose, dose-escalation Healthy adult volunteers Safety/tolerabilityPKImmunogenicity (n=12)3 / 1 mg/kg3 / 3 mg/kg3 / 10 mg/kg3 / placebo Clean safety profileNo dr

  15. Slide 15: Current Summary of In Vitro and In Vivo Preclinical Data

    Current Summary of In Vitro and In Vivo Preclinical Data 15 Lenzilumab does not impede CAR-T cell function in vivoCAR-T cells’ ability to kill cancer remain robust CAR-T control and CAR-T + lenzilumab survival is the same in xenograft model Lenzilumab does not alter in vitro CAR-T-specific cancer ki

  16. Slide 16: Development Plan: Thought Leader Validation

    Lenzilumab Prophylaxis in CAR-T NT Development Plan 16 1 Thought Leader Validation GM-CSF target, preclinical and clinical development plan developed in collaboration with world’s leading CAR-T experts Scientific Advisory Board meeting convened at ASH 2017Significant input and feedback before, durin

  17. Slide 17: Development Plan: Preclinical Development

    Lenzilumab Prophylaxis in CAR-T NT Development Plan 17 Preclinical Development Completed by Dr. Saad Kenderian (Mayo Clinic) using validated animal model Initial data positive Final preclinical data expected Jan/Feb 2018 2

  18. Slide 18: Development Plan: Clinical Development

    Lenzilumab Prophylaxis in CAR-T NT Development Plan 18 Clinical Development Phase 1/2 study design developed by Dr. Sattva Neelapu at MD Anderson – lead investigator for Gilead/Kite’s Yescarta CAR-T Lenzilumab to be studied as prophylactic therapy prior to CAR-T infusion to prevent NTStudy initiatio

  19. Slide 19: Development Plan: Regulatory Submission

    Lenzilumab Prophylaxis in CAR-T NT Development Plan 19 Regulatory Submission Potential adaptive study design to allow roll-over of Phase 1/2 study into potential pivotal registration/approval studyPrecedents for flexibility in approach: tocilizumab was approved with 29 patients, case reports, no con

  20. Slide 20: Development Plan: Value Proposition for Strategic Partner, Deal

    Lenzilumab Prophylaxis in CAR-T NT Development Plan 20 Value Proposition for Strategic Partner, Deal Differentiate a CAR-T offering from competitorsPotentially improve safety, allow for higher CAR-T dosesAssist hospitals/payers with fewer ICU days, readmissionsMove to true out-patient CAR-T treatmen

  21. Slide 21: CMML

    Orphan conditionHigh unmet needUp to 90% of patients have hypersensitivity to GM-CSFPatients typically unsuitable for stem cell transplantFocus on salvage patients with no other treatment options CMML 21 Rare hematologic cancer; recently classified as separate disease with distinct natural history*

  22. Slide 22: Ifabotuzumab: Dosing Begun in Patients with GBM

    Ifabotuzumab: Dosing Begun in Patients with GBM (a Brain Cancer); Potential Use as a CAR-T Construct 22 Ifabotuzumab First-in-class Humaneered mAb for Ephrin type-A receptor 3 (EphA3) Phase 1 bio-imaging study in GBM to enable CAR-T constructCAR design potential using ifabotuzumab backbonePrior clin

  23. Slide 23: Monoclonal Antibody Pipeline

    Monoclonal Antibody Pipeline Indication Phase Anticipated Readout Expected Next Study Value Point Lenzilumab(anti-GM-CSF mAb) Clinical proof of concept *Potential pivot to JMML on interim data Ifabotuzumab(anti-EphA3 mAb) Study to enable CAR construct development Q1 2018 Q2 2018* Q3 2018 Q1 2019 CMM

  24. Slide 24: Anticipated Near-Term Catalysts

    Anticipated Near-Term Catalysts Q12018 Q22018 Q32018 Q42018 Ifabotuzumab Lenzilumab GBM Phase 1 first patient dosed (Melbourne/Brisbane, Australia) GBM imaging results GBM Phase 1 interim imaging data CAR-T animal POC data (Mayo) CAR-T NT Phase 1/2 first patient(MD Anderson) CMML Phase 1 interim rea

  25. Slide 25: Differentiated, Valuable Niche in the Hottest Area of Biotech

    Differentiated, Valuable Niche in the Hottest Area of Biotech – Mitigating Side Effects, Improving Efficacy of CAR-T Obsidian Therapeutics Cell Design Labs HGEN Valuation $49.5MM post-money $567MM acquisition by Gilead($175MM up-front) 12/7/17 ~$50MM* Development stage Pre-clinical Pre-clinical Comp

  26. Slide 26: HGEN Summary

    HGEN Summary CAR-T is one of the hottest fields in biotech; Neurotoxicity the “Achilles Heel’ of CAR-TPositioned to deliver significant value with strong scientific rationale for lenzilumab as prophylaxis to CAR-T NT Working with leading KOLs/CAR-T treatment centers to start lenzilumab phase 1/2 tri

Humanigen — Investor Presentation (January 2018) on 6ix